NCT01105507

The Safety and Efficacy of Canakinumab in Patients Aged 4 Years or Older Diagnosed With Cryopyrin-associated Periodic Syndromes (CAPS) in Canada

An Open Label Study to Assess the Safety, Tolerability and Efficacy of Canakinumab (ACZ885) in Patients Aged 4 Years or Older Diagnosed With Cryopyrin-associated Periodic Syndromes (CAPS) in Canada

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 4 (actual)
• Sponsor: Novartis Pharmaceuticals · Industry
• Sex: All
• Age: 4 Years
• Healthy volunteers: Not accepted

Summary

This study will assess the safety, tolerability and efficacy of canakinumab treatment in Canadian patient diagnosed with cryopyrin-associated periodic syndrome over a period of 18 months.

Conditions

• Cryopyrin Associated Periodic Syndrome

Interventions

Type	Name	Description
DRUG	canakinumab (company code: ACZ885D)

Timeline

• Start date: 2010-08-01
• Primary completion: 2012-05-12
• Completion: 2012-05-12
• First posted: 2010-04-16
• Last updated: 2017-03-21

Locations

2 sites across 1 country: Canada